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ModellingInvestment in vaccine product development should be guided by up-to-date and transparent global bur-
den of disease estimates, which are also fundamental to policy recommendation and vaccine introduction
decisions. For low- and middle-income countries (LMICs), vaccine prioritization is primarily driven by the
number of deaths caused by different pathogens. Enteric diseases are known to be a major cause of death
in LMICs. The two main modelling groups providing mortality estimates for enteric diseases are the
Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Seattle and the
Maternal Child Epidemiology Estimation (MCEE) group, led by Johns Hopkins Bloomberg School of
Public Health. Whilst previous global diarrhoea mortality estimates for under five-year-olds from these
two groups were closely aligned, more recent estimates for 2016 have diverged, particularly with respect
to numbers of deaths attributable to different enteric pathogens. This has impacted prioritization and
investment decisions for vaccines in the development pipeline.
The mission of the Product Development for Vaccines Advisory Committee (PDVAC) at the World
Health Organisation (WHO) is to accelerate product development of vaccines and technologies that are
urgently needed and ensure they are appropriately targeted for use in LMICs. At their 2018 meeting,
PDVAC recommended the formation of an independent working group of subject matter experts to
explore the reasons for the difference between the IHME and MCEE estimates, and to assess the respec-
tive strengths and limitations of the estimation approaches adopted, including a review of the data on
which the estimates are based.
Here, we report on the proceedings and recommendations from a consultation with the working group
of experts, the IHME and MCEE modelling groups, and other key stakeholders. We briefly review the
methodological approaches of both groups and provide a series of proposals for investigating the drivers
for the differences in enteric disease burden estimates.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY IGO license
(http://creativecommons.org/licenses/by/3.0/igo/).
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of diarrhoeal disease aetiology, GEMS and MAL-ED.
The Global Enteric Multicentre Study of Diarrheal Dis-
ease (GEMS)
The GEMS study was a 3-year, prospective, age-stratified,
case-control study to estimate the population burden and
microbiologic aetiology of acute moderate-to-severe diar-
rhoea (MSD). Children aged 0–59 months seeking care for
diarrhoea as outpatients or inpatients at health care centres
(cases) were compared with non-diarrhoeal community con-
trols. In addition, cases were followed up after 2 months to
study short-term mortality after an episode of MSD. The
research was carried out in seven field sites in Southern Asia
and sub-Saharan Africa, using qPCR as a diagnostic tool in
cases and controls to detect evidence of different pathogens
in stool samples and these results were used to estimate the
fraction of moderate-to-severe diarrhoea attributable to each
pathogen.
The Aetiology, Risk Factors, and Interactions of Enteric
Infections and Malnutrition and the Consequences for Child
Health and Development (MAL-ED)
The MAL-ED study was a birth cohort study at eight sites
in South America, sub-Saharan Africa, and Asia. It used a pro-
spective longitudinal design to assess diarrhoea, subclinical
enteropathogen carriage and undernutrition up to the age
of 2 years in a community setting. Among the factors evalu-
ated were enteric infections (with or without diarrhoea) and
other indicators including micronutrient levels, diet, socioe-
conomic status, gut function and environment. The study
examined these factors, their inter-relationships and overall
impact on health outcomes. Because participants were
selected in the community, rather than from among hospital
patients, few children with severe, dehydrating diarrhoea
were observed.1. Background
Whilst it is estimated that diarrhoeal mortality has decreased
by more than 20% from the decade between 2005 and 2015, the
burden of diarrhoea is still significant and predominantly affects
sub-Saharan Africa and South Asia in populations with poor access
to primary healthcare, clean water and sanitation [1].
Today, diarrhoeal diseases with the highest burden in under
five-year olds are considered to be rotavirus, Shigella and Sal-
monella species. Cryptosporidium and enterotoxigenic Escherichia
coli (ETEC) also contribute significantly to overall burden [1]. In
1975, the WHO recommended oral rehydration solution globally
as the standard immediate treatment for acute diarrhea [2], yet
recent evidence suggests that recognition by caregivers may be
poor, and uptake remains low [3]. The routine use of antimicrobials
for diarrhoea in children is only recommended by WHO in clini-
cally severe cases for cholera, shigellosis, dysenteric presentation
of campylobacteriosis and non-typhoidal salmonellosis, or when
the host immune status is severely compromised by severe malnu-
trition or chronic disease [4]. However, with the recognition and
continued emergence of antimicrobial resistance (AMR) [5], partic-
ularly amongst diarrhoea-related pathogens [6,7], additional
approaches to tackling childhood diarrhoea, particularly in LMICs,
must be sought. Future research and development of vaccines
against diarrhoeal pathogens have been highlighted as key priori-
ties to reduce global disease burden [8,9]. There are currently
licensed vaccines for rotavirus and cholera; however, vaccines
are not currently available for any of the other major diarrhoeal
pathogens, although all have candidates in clinical development.
The estimated global burden of disease, and in-particular the
mortality attributable to each pathogen, impacts priority setting
for investment in vaccine research and development (R&D), as well
as policy recommendations for introduction of new vaccines into
immunization programmes. It is important, therefore, that the
methodology used to derive the estimates is well understood,
and accepted, by global stakeholders, including product developers
and policy-makers. Two modelling groups, IHME and MCEE, have
generated estimates of mortality due to the different causes of
diarrhoea. Historically, the global diarrhoea mortality estimates
for children under 5 years of age (U5s) from both groups have been
similar with broad and overlapping confidence intervals [10–12].
However, the most recent iteration of estimates from IHME, GBD
2017 for the year 2016, have diverged from previous IHME esti-
mates, particularly with respect to the numbers of deaths attribu-
ted to specific pathogens, mainly as a result of revisions to the
estimates in high-population, high-burden countries. With the
adoption of new detection technology for diarrhoeal pathogens
in stools and changes to the methodological approach, estimates
of the mortality associated with some pathogens has shifted so sig-
nificantly that investment in some vaccine candidates that are
approaching late-stage clinical testing has been reduced[13].
Because of the implications of changes in disease burden estimates,
in 2018, WHO’s Product Development for Vaccines Advisory
Committee (PDVAC) recommended that an independent working
group be established to evaluate diarrhoeal burden models and
estimates [14].
The enteric burden of disease working group (WG) was estab-
lished and convened in 2018. The initial focus of the WG has been
on the aetiology of diarrhoeal deaths in children U5. Morbidity and
long-term sequelae, though constituting a significant proportion of
the burden from enteric pathogens in this age group, have not yet
been considered by the WG, nor has mortality in older age groups.
However, these factors need to be included in the assessment of
the global burden of various diarrhoeal pathogens and the poten-
tial public health value that a vaccine could offer.This report summarizes the findings from the first meeting of
the WG.2. Objectives of the workshop
The IHME GBD and the MCEE models were reviewed with the
objectives to:
(I) Identify areas of commonality and divergence across
methodologies and assumptions.
(II) Develop recommendations and identify areas for further
work that may inform future iterations of the diarrhoeal
aetiology-specific mortality assessments for U5s.
(III) Increase the transparency and understanding of how aetiol-
ogy estimates are derived.
The sections below outline the main methodological
approaches of the two modelling groups, highlighting similarities
and differences. We use Shigella and ETEC as examples to show
the divergence in modelled estimates between the groups. Refer-
ence will be made to two large landmark epidemiology studies,
namely the Global Enteric Multicentre Study of Diarrheal Disease
(GEMS) [15] and the Aetiology, Risk Factors, and Interactions of
Enteric Infections and Malnutrition and the Consequences for Child
Health and Development study (MAL-ED) [16] (see Box 1). Finally,
a set of proposals are presented as future work to explore varia-
tions in the model outputs and to provide updated evidence for
key assumptions applied by both modelling groups.
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infections
Both the IHME and MCEE modelling groups employ a step-wise
process for generating under-five all-cause and pathogen-specific
diarrhoea mortality estimates. The first stage is to generate esti-
mates for all-cause mortality in U5s. This is then disaggregated into
the percentage of U5 deaths due to diarrhoea, and then, estimates
for deaths attributed to individual pathogens are generated (Fig. 1).
Table 1 compares differences in these first two key outputs from
the two modelling groups and provides information on differences
in data sources and inclusion and exclusion criteria applied to gen-
erate the estimates. In addition, estimates for ETEC and Shigella are
provided, comparing 2011 estimates for MCEE and 2013 for IHME
from earlier studies, as an example of deaths attributed to different
pathogens during the third stage. Data from IHME 2016 are also
shown, data for MCEE 2016 will not be made publicly available.
In this section, we outline the first two stages shown in Fig. 1
and then provide a more detailed overview of the third stage
employed by each group to generate estimates of the numbers of
diarrhoeal deaths attributable to different aetiologies, highlighting
key similarities and differences in Section 4.Table 1
Differences in data sources used and estimates generated for the envelope of U5 deaths an
percentage of U5 diarrheal deaths due to Shigella and ETEC are provided as examples to s
Model output IHME (2016)1
U5 Mortality Envelope (2017)
(Stage 1)
IHME-generated estimates
56M (54M-59M)
U5 Deaths Due to Diarrhoea
(Stage 2)
Data included:
 Vital registration studies with >60% d
completeness.
 Verbal autopsy data from demographic surve
lance and surveys
549 K (491–606 K)
U5 Diarrheal Deaths Due to
Pathogens: (Stage 3)
Shigella: ETEC:
 All hospital and community studies conduct
for 12 or more months.
 GEMS and MAL-ED studies.
Model output IHME (2016)
Shigella 99 680 (59550–161235)
ETEC 15 960 (4400–40300)
IHME (2011)3
Shigella 33 400 (24 900–43500)
ETEC 23 100 (17000–30400)
Comparison of modelling results and data inputs for IHME and MCEE for Total U5 mortali
percentage U5 diarrheal deaths due to Shigella and ETEC (2016 GBD IHME, 2017 MCEE
1 Data extracted from GHDx website for the Global Burden of Disease 2017 Model, re
2 Data from Pneumonia and Diarrhea Progress Report, 2018. John Hopkins, Internatio
3 Data from Global, regional, and national age-sex specific all-cause and cause-specific
Burden of Disease Study 2013. Lancet 2015, Jan 10; 385(9963): 117–171.
4 Data from Global Causes of Diarrheal Disease Mortality in Children <5 Years of Age:
Stage 1 Stage 2 Stage 3
Envelope of U5 
deaths
% of U5 deaths 
due to diarrhoea
% of U5 diarrheal 
deaths due to 
each pathogen
Fig. 1. Three stage process for generating U5 diarrheal deaths due to different
pathogens.3.1. Generation of the total global envelope for all-cause U5 mortality
globally
For the 2017 iteration, the IHME model uses IHME-generated
estimates for all demographic inputs. The MCEE model uses United
Nations Inter-agency Group for Child Mortality Estimation (UN
IGME) modelled estimates, generated using UN Population Divi-
sion demographic data of population, fertility, migration and mor-
tality by age, sex, location and time, from national censuses and
specialised surveys [17]. Despite these differences in the source
data, the overall U5 mortality estimates generated by each group
are similar; 56M (95%UI, 54M-59M) for IHME and 54M (90%UI,
52M-58M) for MCEE. However, it should be noted that there are
significant differences between the mortality estimates in different
geographic locations. Thus, differences in the all-cause envelope at
a country or regional level, used by the IHME modellers, could lead
to differences in the estimated number of total diarrhoea deaths
for individual regions between IHME and MCEE. For each revision
of the GBD estimates, both groups update all of their values for pre-
vious years.
The second output is an estimate for the percentage of U5
deaths due to diarrhoea. Both IHME and MCEE use vital registra-
tion, verbal autopsy and surveillance system data to inform the
estimate of percentage of U5 deaths due to diarrhoea. However,
there are differences in the data used by each of the groups, with
respect to inclusion and exclusion criteria and access to unpub-
lished data. The MCEE group have more stringent inclusion and
exclusion criteria for the threshold completeness of vital registra-
tion data: MCEE only accepts studies with >80% data complete
whereas IHME includes studies with > 60% data completeness.
To generate diarrhoeal-specific estimates, IHME redistributes
deaths that cannot be atrtibuted to a pathogen to specific causes
of death (like diarrhoea) and uses an internal model called the
Cause of Death Ensemble model (CODEm), a Bayesian hierarchical
model to generate, by location, age group (four age groups underd percentage of U5 deaths due to diarrhoea, by MCEE and IHME. A comparison for the
how the variation at the level of aetiology.
MCEE (2016)2
Generated by the United Nations Group for Child Mortality Estimates (UN
IGME)
54M (52M-58M)
ata
il-
Data included:
 Vital registration studies with >80% data completeness.
 Verbal autopsy data from demographic surveillance and surveys.
477 K (375–555 K)
ed  Hospital inpatient studies conducted for 12 or more months.
 GEMS and MAL-ED unpublished studies including data stratified by
inpatient vs. outpatient/community.
MCEE (2016)
Data will not be made publicly available
Data will not be made publicly available
MCEE (2013)4
28 000 (12000–53000)
42 000 (20000–76000)
ty envelope (2017) and percentage U5 deaths due to diarrhoea (2017). Estimates for
(unpublished)) are also shown.
porting data for 2016.
nal Vaccine Access Centre.
mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global
A Systematic Review. PLOS One 2013, 4 Sept. 8(9).
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diarrhoea. Table 1 provides information on the data sources used
for the first two stages in the process.
The procedures used by both groups to generate the percentage
of U5 diarrheal deaths due to different pathogens, which was the
major focus of the workshop. Differences in methodological
approaches between groups at this stage are most likely to
contribute to the divergence seen in pathogen-specific mortality
estimates (aetiology). In Section 4, each step in the process is sum-
marised and an explanation of similarities and differences in the
modelling approaches are reviewed, highlighting the strengths
and limitations of the methodologies used by each group.4. Process for calculating the percentage of diarrheal deaths due
to individual pathogens
4.1. Generation of a diarrheal mortality proxy
Due to a lack of representative datasets in which deaths due to
specific diarrhoeal pathogens have been identified, the initial step
in the process of attributing diarrhoeal deaths to specific patho-
gens is to identify a proxy measure. Both groups use the proportion
of diarrheal episodes in which a particular pathogen is detected as
the proxy measure; however, IHME use data from both hospital
inpatient and outpatient studies and MCEE uses only data from
hospital inpatient studies, assuming that hospitalization is a more
accurate proxy for mortality and that aetiologic fractions differ
between inpatient and outpatient studies. Both groups only use
studies which were conducted for 12 or more months. Studies
which did not stratify data from inpatients, outpatients and the
community were excluded by MCEE. Facility-based studies of both
inpatients and outpatients are thus only included if inpatient-
specific proportions are reported or raw data are available to allow
subset analysis with the exception of the GEMS and MAL-ED stud-
ies, for which unpublished stratified data were obtained. Both
IHME and MCEE include only diarrhoea proportion data from stud-
ies with a minimum of 100 samples tested and conducted for
longer than one year, and not restricted to specific subpopulations.
The proportion positive in hospitalised and ‘severe’ episodes are
tracked, and all data meeting inclusion criteria is used in the mod-
els [18]. All data for hospitalised/severe diarrhoea relative to com-
munity/outpatient are included in the model, including all eligible
GEMS data. A summary is given in Table 2.
4.1.1. Strengths and limitations
The approach of IHME is to use all available data with limited
restrictions, whilst MCEE have stringent inclusion and exclusion
criteria for data. The inclusion of ‘severe’ cases as well as hospi-
talised cases allows both inpatient and outpatient data to be used
for IHME’s model estimates. However, there is variation between
studies in what may constitute a ‘severe’ case (i.e. the case defini-
tion), and the interpretation of this, which may limit data quality.
The IHME approach uses more data compared to MCEE, although
there is likely to be a large proportion of studies that were included
by both modelling groups. A comparative analysis of the criteria for
data inclusion, data sources and data quality of the modelling
groups could help to optimize approaches for the next iterationsTable 2
Summary of data used by IHME and MCEE for generating diarrheal mortality proxy.
Model Methodology IHME
Generation of diarrheal mortality proxy Include hospitalised and ‘severe’ dia
Include inpatient, outpatient, and co
All eligible GEMS and MAL-ED dataof models, ensuring that future diarrhoeal disease models abide
to a high and consistent standard of data quality.
4.2. Validity of epidemiology studies to be included
Both groups use systematic literature reviews that date back to
1985 (IHME) or 1990 (MCEE), to extract pathogen prevalence from
studies meeting their inclusion and exclusion criteria. This
includes, where available, data from scientific literature on differ-
ent aetiologies, hospital data, population survey data, and data
from unpublished sources, including detailed data for the GEMS
and MAL-ED studies and more recent cohort studies.
4.2.1. Strengths and limitations
The validity of using studies dating back to the 1980’s by both
groups, in terms of robustness and reproducibility of diagnostic
methods compared to more recent studies, is highlighted as a
potential limitation. The improvement over time in culture-based
and other diagnostic techniques as well as likely shifts in the aeti-
ology of diarrhoeal disease, due to initiatives such as Water, Sani-
tation and Hygiene (WASH), may suggest that, for contemporary
estimates, a greater weighting should be placed on more recent
studies [19]. Additionally, evidence from GEMS shows that using
qPCR to test stools for different pathogens is more sensitive than
culture-based methods, compared to culture-based methods [20],
with the consequence that older diagnostic reporting from older
studies may underestimate the prevalence of pathogens which
require more sensitive techniques for detection. There is a need
for sensitivity analysis to test for reliability of these data, and
groups should consider the potential effect of attributing greater
weighting to more recent studies or incorporating time and/or
time-varying covariates in the models [21], given the improvement
in diagnostics.
4.3. Data processing methodologies and the use of qPCR data
4.3.1. IHME approach
The final step in the generation of estimates for individual
pathogen mortality is data adjustment and processing. In the case
of IHME, epidemiological data extracted from the literature, hospi-
tal data, and population survey data are analysed using their Dis-
Mod tool (Bayesian hierarchical meta-regression tool) to estimate
the proportion of diarrhoeal cases that are caused by different
organisms. In order to adjust for the different pathogen detection
methods used, GEMS and MAL-ED data are used to calculate the
sensitivity and specificity of laboratory diagnostic tests, such as
culture and immunoassay, relative to qPCR, for each pathogen
and a qPCR adjustment factor is applied to the pathogen-specific
proportions after the model is run. A major short-coming of diar-
rheal disease studies conducted prior to GEMS has been the failure
to perform comprehensive assessment of major enteric pathogens,
due to demanding technical approaches, in settings with high bur-
dens, often lacking the necessary laboratories and diagnostics [22].
The correction factor generated from GEMS and MAL-ED is then
applied to the modelled results and adjusted for sensitivity and
specificity based on this estimate. The modelled proportion of diar-
rhoeal cases by aetiology are adjusted and produce estimates for
each location, year, age, and sex. IHME then use a counterfactualMCEE
rrheal episodes. Included only hospitalised episodes.
mmunity-based data. Include only inpatient data.
included. Only GEMS and MAL-ED inpatient data included
4796 H.J. Prudden et al. / Vaccine 38 (2020) 4792–4800approach to calculate a population attributable fraction (PAF) for
each pathogen, which represents the relative reduction in hospi-
talised diarrhoea episodes (as a proxy for deaths) if exposure to a
given aetiology was to be eliminated. In order to generate this,
GEMS case-control data are used to calculate pathogen-specific
odds ratios (ORs) by age where the OR is the odds of diarrhoea
given the presence of that pathogen in the stool at a diarrhoea-
attributable quantity as detected by qPCR, divided by the odds of
diarrhoea without the detection of the pathogen at a diarrhoea-
attributable quantity. This is combined with the qPCR-adjusted
proportion of diarrhoea cases positive for a given aetiology to cal-
culate the pathogen-specific PAF. Such that:PAF ¼ Proportion  1 1
OR
 
The PAF is applied to calculate deaths due to diarrheal aetiolo-
gies by location, year, age, and sex. The schematic in Fig. 2, below,
summarises the IHME data processing methodology.
For all pathogen aetiologies except Vibro cholerae and Clostrid-
ium difficile, the PAF is calculated from the proportion of diarrhoea
cases that test positive for each aetiology and the OR of having
diarrhoea if the pathogen is detected. Since diarrhoea can be
caused by co-infections with multiple pathogens, PAFs can overlap
and therefore add up to more than 1. The purpose of using ORs is to
address the issue of subclinical carriage, namely that enteric patho-
gens are frequently detected in the absence of diarrhoea. For each
pathogen, PAFs and uncertainty intervals are multiplied by the
diarrhoea mortality envelopes to estimate age-, sex-, location-
and year-specific pathogen deaths.Epidemiological 
data
Global Enteric 
Mulcentre 
Study (GEMS) 
data
Dismod-MR to 
esmate 
proporon in 
diarrhoeal cases 
by aeology
Sensivity and 
specificity of lab 
diagnosc to 
qPCR case 
definion
Correct pr
esmat
sensiv
specifi
compared
defin
Calculate ORs by 
age from qPCR 
data
Fig. 2. Data processing mechanism for IHME data (adapted from GBD Diarrhoeal Disease
aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Diseas
Epidemiological 
data (hospital 
data)
GEMS - based 
definion of 
pathogenicity 
applied
Pathogen -
specific 
proporons
calculated
Age group 
conversion fact
applied
Fig. 3. Data processing mec4.3.2. MCEE approach
MCEE takes a different approach. They do not adjust studies and
data where pathogens are detected using non-qPCR detection
methods to match with those detected by qPCR. However, MCEE
uses pathogen positivity according to GEMS qPCR to define
pathogenicity. Organisms with <2 site- and age-specific attributa-
ble fractions that were different to 1 (not associated with causing
diarrhoea) in the GEMS qPCR re-analysis [20] (including norovirus
G1, atypical EPEC, LT-ETEC, Giardia, EAEC) were excluded from the
analysis. Mean age-adjusted pathogen-specific proportions were
calculated from hospital data, with age-group conversion factors
applied to convert pathogen-specific proportions reported for nar-
rower age ranges than 0–59 months, based on data from studies
that reported estimates across age ranges. A global median was
used to estimate pathogen-specific proportions for regions with
missing data. The pathogen proportions (in addition to the
unknown proportion, derived from GEMS qPCR hospital inpatient
data) are constrained to add up to 1 overall and by region
(Fig. 3). Uncertainty bounds are generated using bootstrap tech-
niques. Final pathogen-specific proportions and uncertainty inter-
vals are multiplied by regional diarrhoea mortality envelopes by
year to generate regional estimates of pathogen-specific deaths.
4.3.3. Strengths and limitations
Samples from the GEMS study have recently been reanalysed
using qPCR methods rather than the culture-based and other
microbiological methods that were used in the original study. This
has led to a re-estimation of the percentage of diarrhoea attributa-
ble to a named pathogen, with 89% of all episodes attributed to a
pathogen, compared to 52% in the original GEMS analysis [20]. Inoporon 
es for 
ity and 
city 
 to qPCR 
ion
Adjust proporons 
by 
locaon/year/age/
sex
Calculate PAF 
and then apply 
to diarrhoeal 
deaths
s Collaborators. Estimates of global, regional, and national morbidity, mortality, and
e Study 2015. Lancet Infect Dis 2017).
 
or 
Proporon of 
infecons by 
aeology 
constrained to 
add up to 1
hanism for MCEE data.
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adjust for differences in sensitivity and specificity for all PCR and
non-PCR estimates, whilst MCEE does not, but plans to do so in
the future. There are two main limitations in using the GEMS data.
Firstly, the use of a single adjustment for each pathogen derived
from GEMS ignores substantial heterogeneity across studies in
the relative sensitivity between diagnostics. Secondly, the absence
of diagnostic metadata in the IHME database combined with the
increasing incorporation of molecular diagnostics may lead to
over-correction, particularly among more recent studies that use
PCR.
4.4. Approaches to infer aetiology in the presence of high-rates of
subclinical pathogen detection
4.4.1. The use of PAF versus pathogen prevalence
Currently, only IHME uses ORs to calculate the pathogen-
specific mortality and population attributable risk, whilst MCEE
use the pathogen prevalence (the prevalence of individual patho-
gens from the studies). Both groups consider evidence from multi-
ple pathogen studies, thereby addressing the issue of mixed
aetiologies. This gives rise to the issue of subclinical carriage,
where a pathogen may be present but is not responsible for symp-
toms. This approach relies heavily on the assumption that the ratio
of the prevalence of a pathogen in cases compared to controls is a
clear indicator of pathogenicity. This assumption may be too con-
servative, especially in high incidence settings [23,24] and in-
particular for pathogens that commonly cause reinfection. Such
is the case for many enteric pathogens that often cause asymp-
tomatic or subclinical infection.
IHME does not constrain the PAFs to add up to 1, and therefore
they assume that in instances where multiple pathogens are
detected, diarrhoea would still occur even if one of the pathogens
was removed. MCEE also considers mortality attribution may be a
result of multiple pathogens, but they do constrain the pathogen
prevalence envelope to add up to 1 minus the proportion of diar-
rhoea without a known cause (restricting to the inclusion of patho-
gens that were statistically significantly associated with diarrhoea
in the GEMS qPCR re-analysis). Burden estimates could be signifi-
cantly inflated, if subclinical carriage (presence of a pathogen,
which is not severe enough to present observable symptoms) is
not considered, by way of calculating attributable fractions. In
addition to this there may be variation in pathogen load needed
to cause infection between sites, i.e. variations in the probability
of clinical symptoms caused by a certain pathogen in different set-
tings, which would lead to a restriction in the generalizability of
assumptions. It therefore remains unclear how often ‘true’ aetio-
logic mixed infections occur. Evidence from qPCR shows high vari-
ation in durations of carriage of subclinical infections, and there is
also evidence to suggest infections could be sequential rather than
mixed [25,26]. The implications of this are that, in cases where a
pathogen is consistently shed and there are high levels of detection
but suspected low levels of pathogenicity within a site, country, or
region, the OR may be over- or under-estimated.
4.4.2. Strengths and limitations
A strength of the current approach of both groups is the consid-
eration of sub-clinical infections, but there is a lack of knowledge
on how to interpret the information and estimates of the burden
of sub-clinical infections which are not generated by either group.
The presence of sub-clinical infection may vary geographically for
individual pathogens, such that the occurrence of one pathogen
may cause symptoms in one setting but not in another. A further
limitation is lack of knowledge on whether co-infections enhance
the probability of clinical symptoms and how different pathogens
interact and impact aetiology in the presence of others. This ispotentially further complicated by geographical variations and a
lack of understanding on whether infections are ‘mixed’ or ‘se-
quential’. For IHME, these combined factors may result in hetero-
geneity of ORs that complicates the use of a single ‘global’
median OR for each pathogen to calculate PAFs, currently adopted
by IHME. A potential solution, to strengthen the approach adopted
by IHME, may be to generate ORs across similar geographical
regions and population archetypes, based on the proportion of
pathogens excreted in diarrheal and non-diarrheal stools. How-
ever, the sparsity of data on pathogen prevalence that is currently
available from healthy controls limits this option, and additional
control samples from geographical areas would need to be gener-
ated. This is also a limitation for the MCEE group, who considers
that mortality may be attributed to multiple pathogens, with
pathogen prevalence informing aetiology. Additional information
on pathogen prevalence in healthy controls, would likewise help
to also strengthen MCEE’s approach.
4.5. Other key strengths and limitations in the generation of individual
pathogen estimates
4.5.1. Data extrapolation
In order, to produce global estimates for individual pathogen
estimates, IHME extrapolate the ORs derived from children under
5 years of age from Africa and Asia (GEMS) to all estimates, includ-
ing adults and in developed countries. Prevalence of each pathogen
is estimated for both ages and locations where data do not cur-
rently exist, and models are continually updated. Whilst in many
instances, sub-regional data may be able to predict country-level
burden attribution with a high degree of confidence, it is possible
that outliers, where data quality is poor or is not reflective of
sub-regional estimates, may result in inaccurate estimates for
some countries. MCEE use a global median to estimate pathogen-
specific proportions for regions with missing data. This is reliant
on the data being a good proxy for other regional estimates, and
it is not clear if this is always the case.
4.5.2. Assumption of pathogen homogeneity in case fatality ratios
Both modelling approaches assume that the distribution of
pathogen aetiology as assessed via each group’s accepted proxy
measure directly reflects the distribution of mortality, such that
detection of every pathogen in a hospitalized or severely ill child
is assumed to be equally likely to cause death. MCEE assume that
case fatality ratios are the same across all pathogens based on
the prevalence estimate they generate when they scale
pathogen-specific proportions. The same implicit assumption is
made by IHME, when they generate PAFs. If indeed, there is varia-
tion between pathogens, this will affect the distribution of patho-
gen aetiology in patients who die from diarrhoea and may also
be dependent on geography, socio-economic status and popula-
tion. More evidence is needed to explore variations in case-
fatality rates for individual pathogens. This is challenging because
the majority of data on mortality is obtained in hospital settings
and therefore may bias estimates, given that untreated severe diar-
rhoea within the community, particularly in LMICs, is more likely
to result in death, in most cases. Data collected from study sites
is also extrapolated at country-level, which may not necessarily
be representative. Whilst this is a limitation, to address this issue
of generalisability would be particularly difficult.5. Proposals for addressing knowledge gaps and improving
model estimates
There are both strengths and limitations to the methods pre-
sentedbyboth IHMEandMCEEgroups, as outlinedabove.Webelieve
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understanding themain reasons for variations in aetiology estimates
within thepublisheddiarrhoeamortality envelope forU5s. Threekey
thematic areas were proposed for future investigation.
(1) How differences in data inputs impact the distribution of U5
aetiology estimates within the mortality envelope.
Identifying the drivers for differences between the modelling
outputs produced by IHME and MCEE will be a key step in helping
to quantify and assess the source of differences in estimates.
Whilst much of the data used by both groups are expected to be
common and comparable, there are important differences in the
criteria that determine which data are included. An improved
understanding of factors that are the strongest determinants of
the model estimates is vital to better understanding their accuracy
and robustness, since these estimates drive decision-making with
respect to vaccine development and introduction. The impact or
trade-off of utilising a small number of high-quality studies (as
MCEE do) versus a larger number of studies of varying quality (as
IHME do), to generate global estimates needs to be investigated.
Additionally, the validity of using historical studies that use less
sensitive diagnostic techniques, weighted equally within the data
analysis, needs reviewing.
To investigate these steps, we propose the following strategies,
to be refined in an iterative manner as greater understanding of the
processes evolve:
i. Conduct a systematic comparison of studies and data
included in both models, in an effort to understand how data
selection criteria and access to data impacts on the quality
and quantity of studies used.
ii. Agree on a standardised dataset to directly compare how dif-
ferences in model structure and associated assumptions
(rather than input data) impact estimates.
iii. Conduct a data grading review to improve understanding of
the quality and standard of data used by each group, fol-
lowed by a model sensitivity analysis to explore the impact
of inclusion and exclusion criteria on model estimates.
(2) How extrapolation of odds ratios from 7 GEMS sites in Africa
and Asia impacts global aetiology estimates.
There were concerns regarding potential bias resulting from the
use of GEMS data to determine global median ORs or pathogens,
given substantial variation in the rates of subclinical pathogen car-
riage across ages and settings. Concerns were further raised
regarding the direct use of odds ratios exclusively from seven
GEMS sites and extrapolation of this data regionally and to older
age groups (5–99 years, for Global Burden of Disease). There was
a desire to improve our understanding of the relationship between
the presence of pathogen and diarrhoea by utilising additional data
from controls to provide more geographically representative ORs
which can be consistently used in future modelling analysis, for
both IHME, MCEE and other groups. Recommendations included:
i. Conduct a systematic review to identify studies that tested
for the presence of key diarrheal pathogens among non-
diarrheal controls and older age groups.
ii. Use the findings to carry out a careful and comprehensive
statistical approach using network meta-analysis to assess
variability in odds ratios within and across regions and set-
tings, built through consensus with IHME and MCEE.
(3) Heterogeneity in case fatality ratios (CFRs) for different
pathogens.There is a strong recommendation to assess potential variability
in CFRs, particularly in-light of the high number of co-infections
and sub-clinical carriage reported in study participants in low-
and middle-income countries, and to assess the relationship
between the OR of disease and risk of death. This approach will
need to account for the different approaches taken by each of the
modelling groups, since neither group uses CFR in its current
methodology, to ensure the process provides useful information
that can be adapted and applied by both MCEE and IHME in the
future. A limitation is the potential scarcity of data available for
non-hospitalised (community) estimates of death (as previously
alluded to), which will likely introduce bias since treatment within
a hospital setting is likely to significantly increase chances of sur-
vival. Additionally, mortality may be affected by the rate of onset of
illness and time to death (which may affect the probability that a
child with diarrhoea reaches a facility), and this may vary depend-
ing on the pathogen. Factors such as economic status and geogra-
phy are also important. To address this issue, there was a
recommendation to:
i. Carry out a systematic literature review to identify the CFR
for selected enteric pathogens. The review should aim to
include both hospital and non-hospital data (with the caveat
that the latter may be very limited; and that hospitalization
changes the CFR for largely treatable infections, like
rotavirus.).
6. Discussion
The global mortality due to diarrhoeal disease is declining, and
for some pathogens, such as ETEC, the current (GBD 2017 for the
year 2016) IHME burden of disease estimate is now considered
too low to warrant prioritization of vaccine development by some
stakeholders. However, given the variation between mortality esti-
mates from different groups, the methodology and robustness of
each estimate needs to be carefully understood and investigated.
For this reason, WHO’s PDVAC recommended the formation of an
independent working group to evaluate these aspects. As we have
discussed here, we identified several elements of the methodology
that we suggest, be further investigated.
The proposed systematic review to extract data from healthy
controls will help to further explore the relationship between the
presence of a pathogen and disease. It is expected there will be a
degree of geographical variation within the results, to complement
the current GEMS data, which assumes homogeneity across sites
for the odds ratios. This additional information may help to better
explain geographical differences in the susceptibility of individuals
and populations to certain pathogens, and thus provide improved
information on burden.
The results from the second systematic review will explore the
likelihood of mortality given the presence of disease, known as the
case fatality ratio, for individual pathogens. The current strategy
employed by both modelling groups is to assume equal likelihood
of death regardless of the aetiology. This is likely to over-estimate
the risk of mortality for some pathogens and under-estimate the
risk for others. A clearer understanding of the variation in case
fatality ratio will be of great importance in informing vaccine
development, particularly for pathogens which are associated with
a higher risk of mortality.
7. Conclusion
The modelling approaches employed by both the IHME and
MCEE groups have historically provided well-regarded results that
have guided policy recommendations. As new data, diagnostic and
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is essential to ensure more reliable estimates. However, the inter-
pretation and use of new evidence should be subject to a high level
of scrutiny, and where appropriate, new guidelines developed for
its use. In addition, it will be important to address gaps within
the data that give rise to inconsistencies and less reliable informa-
tion. Emerging evidence generated through studies, such as The
Child Health and Mortality Prevention Surveillance (CHAMPS)
study, designed to track definitive causes of child mortality in sites
throughout Asia and sub-Saharan Africa through minimally inva-
sive tissue sampling, will help to provide validation on key mea-
sures such as the diarrhoeal mortality proxy. More generally,
steps can be taken to assess the quality of data employed by mod-
elling groups, and systematic reviews can be undertaken to
address other key gaps in the evidence.
Future modelling work, should also assess the longer-term
sequalae of diarrhea [27,28], including growth failure and cogni-
tive impairment in the earlier years of life, as well as metabolic
syndrome in the later years of life [29]. There is evidence also that
repeated infections may increase risk of death from other unre-
lated infectious diseases such as pneumonia and malaria [30].
Whilst the GBD estimates include growth deficits in their estima-
tion of diarrhoea-specific DALYs, they do not consider neurodevel-
opment due to the absences of standard routinely collected metrics
of neurodevelopment. Future models should incorporate these
longer-term effects and risk factors, in addition to the effects of
acute diarrhoea. This will further strengthen the evidence-base
for decision-making around prioritizing enteric pathogens for
which vaccines would have the greatest public health impact.
There is a clear case for ensuring diarrhoeal pathogen mortality
estimates are constantly reviewed and updated, and adequate
resources are made available to ensure model comparison exer-
cises, since these are a core component of vaccine priority evalua-
tions. This work will serve as an example of the importance of
critically assessing data quality in modelling exercises, whilst iden-
tifying and addressing crucial gaps in the evidence which must be
addressed.
The proposed work aims to provide a thorough assessment of
the current data and approaches used by IHME and MCEE groups.
Our hope is that this can include a sensitivity analysis of the model
input data to improve understanding of key input variables, poten-
tially leading to improved guidance for data use, and enhanced
interpretation of model results to guide decision-making. Whilst
the activities outlined above help to better define which pathogens
should be prioritized for vaccine development, future work should
include assessment of data and model to quantify the impact of
longer-term sequelae. Collectively, robust data and burden models
are imperative for building the evidence-base to inform prioritiza-
tion and policy decisions.8. Role of the funders
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